Skip to main content

Table 3 Association between GSTP1 methylation (considered as a continuous variable, per each 1% increase) and the risk of prostate cancer detection stratified by Gleason score and ward

From: DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer

GSTP1

ORs of prostate cancer for methylation level in the second biopsy

ORs of prostate cancer for the highest† methylation level between the first and second biopsy

OR1 (95% CI)

OR2 (95% CI)

OR1 (95% CI)

OR2 (95% CI)

Gleason score

 6 or 3 + 4

1.14 (1.02 to 1.27)

1.10 (0.97 to 1.25)

1.19 (1.06 to 1.35)

1.18 (1.03 to 1.34)

 at least 4 + 3

1.33 (1.08 to 1.62)

1.22 (0.96 to 1.57)

1.27 (1.07 to 1.51)

1.21 (0.98 to 1.48)

ward

 Ward I (86 cases, 100 controls)

1.17 (1.03 to 1.32)

1.13 (0.99 to 1.30)

1.19 (1.06 to 1.34)

1.17 (1.03 to 1.33)

 Ward II (25 cases, 29 controls)

1.26 (0.96 to 1.66)

1.08 (0.77 to 1.52)

1.61 (1.04 to 2.49)

1.58 (0.92 to 2.71)

  1. OR odd ratio, CI confidence interval
  2. OR1 adjusted for matching variables (ward and time distance between the first biopsy and the index sampling)
  3. OR2 adjusted for the matching variables, age and year at the first biopsy and prostatic specific antigen (PSA) at the second biopsy (continuous variables are centered at their mean)
  4. †For example, if methylation in GSTP1 is 4% in the first biopsy and 7% in the second biopsy, the highest level used for this analysis is 7%
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us